دورية أكاديمية
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.
| العنوان: | KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination. |
|---|---|
| المؤلفون: | Rosell, Rafael, Jantus-Lewintre, Eloisa, Cao, Peng, Cai, Xueting, Xing, Baojuan, Ito, Masaoki, Gomez-Vazquez, Jose Luis, Marco-Jordán, Mireia, Calabuig-Fariñas, Silvia, Cardona, Andrés Felipe, Codony-Servat, Jordi, Gonzalez, Jessica, València-Clua, Kevin, Aguilar, Andrés, Pedraz-Valdunciel, Carlos, Dantes, Zahra, Jain, Anisha, Chandan, S, Molina-Vila, Miguel Angel, Arrieta, Oscar, Ferrero, Macarena, Camps, Carlos, González-Cao, Maria |
| المصدر: | Cell Commun Signal ; ISSN:1478-811X ; Volume:22 ; Issue:1 |
| بيانات النشر: | BioMed Central |
| سنة النشر: | 2024 |
| المجموعة: | PubMed Central (PMC) |
| الوصف: | KRAS-mutant non-small cell lung cancer (NSCLC) shows a relatively low response rate to chemotherapy, immunotherapy and KRAS-G12C selective inhibitors, leading to short median progression-free survival, and overall survival. The MET receptor tyrosine kinase (c-MET), the cognate receptor of hepatocyte growth factor (HGF), was reported to be overexpressed in KRAS-mutant lung cancer cells leading to tumor-growth in anchorage-independent conditions. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1186/s12964-024-01667-xTest; https://pubmed.ncbi.nlm.nih.gov/38867255Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11167791Test/ |
| DOI: | 10.1186/s12964-024-01667-x |
| الإتاحة: | https://doi.org/10.1186/s12964-024-01667-xTest https://pubmed.ncbi.nlm.nih.gov/38867255Test https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11167791Test/ |
| حقوق: | © 2024. The Author(s). |
| رقم الانضمام: | edsbas.C2CBF50 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1186/s12964-024-01667-x |
|---|